Clinical Trials Browser

Phase 3 × Has results × cemiplimab × Clear all

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03257267 2025-04-08

Study of Cemiplimab in Adults With Cervical Cancer

Phase 3 Completed

608 enrolled 18 charts

Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03515629 2022-11-16

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Phase 3 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung